Evidence map›Paper›PMID 35372084›Full record

ArticleFrontiers in oncology2022

Prognostic Pathways Guide Drug Indications in Pan-Cancers.

Fanlin Meng, Kenan Zhang, Changlin Yang, Ke Zhang, Quan Xu, Ruifang Ren, Yiming Zhou, Yimin Sun, Yan Peng, Yanze Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Assessment of Financial Impact of Expanding the Scope of Drug Usage in South Korea.International journal of health policy and management · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fanlin MengMarketing and Management Department, CapitalBio Technology, Beijing, China.
Kenan ZhangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Changlin YangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Ke ZhangNational Engineering Research Center for Beijing Biochip Technology, Beijing, China.
Quan XuNational Engineering Research Center for Beijing Biochip Technology, Beijing, China.
Ruifang RenNational Engineering Research Center for Beijing Biochip Technology, Beijing, China.
Yiming ZhouNational Engineering Research Center for Beijing Biochip Technology, Beijing, China.
Yimin SunMarketing and Management Department, CapitalBio Technology, Beijing, China.
Yan PengMarketing and Management Department, CapitalBio Technology, Beijing, China.
Yanze LiMarketing and Management Department, CapitalBio Technology, Beijing, China.
Hongyan GuoNational Engineering Research Center for Beijing Biochip Technology, Beijing, China.
Yonghong RenMarketing and Management Department, CapitalBio Technology, Beijing, China.
Zheng ZhaoBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathway-level analysis is a powerful approach enabling the interpretation of post-genomic data at a higher level than that of individual molecules. Molecular-targeted therapy focusing on cascade signaling pathways has become a new paradigm in anticancer therapy, instead of a single protein. However, the approaches to narrowing down the long list of biological pathways are limited. Here, we proposed a strategy for

Indexed as

herbspan-cancerspathways“TCM-pathways-cancers” tripletstraditional Chinese medicines (TCMs)

Identifiers

PMID35372084
PMCPMC8964428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.